Peptide Education Center / Safety Bulletin
Public Safety Alert · Reviewed September 3, 2026Federal cases and FDA actions show how counterfeit, misbranded and “research-only” injectables can enter the American market. This page separates documented facts from allegations—and evidence from fear.
A label can be printed in seconds. Sterility, identity, potency and medical accountability cannot.
Authorities have documented illegal importation, repackaging, counterfeit products, unsanitary manufacturing, dosing errors and at least one related online-injectable contamination case with significant, potentially life-threatening injury.
We did not find an authoritative U.S. government case proving death or permanent disability directly caused by BPC-157, TB-500, CJC-1295 or ipamorelin. That absence does not establish safety; it means the public human evidence is incomplete and claims must remain precise.
Each entry identifies its legal status and whether the public record describes patient harm. Charges remain allegations unless and until proven.
Federal prosecutors allege a licensed physician obtained discounted, inadequately tested products from China and administered substances including semaglutide, tirzepatide, retatrutide, cagrilintide, BPC-157, TB-500, ipamorelin and CJC-1295 to more than 200 patients.
A couple imported drugs from China, repackaged them with “For Research Purposes Only” labels and sold them while knowing customers intended to ingest or inject them. DOJ reported more than $2.5 million in gross revenue.
DOJ reported that an Alabama defendant made unapproved cancer-treatment products in nonsterile conditions, imported materials from China and concealed human use behind research labeling.
A physician pleaded guilty after administering unapproved semaglutide obtained from unauthorized suppliers. Some vials were labeled for research only, and prosecutors said patients were not told.
Federal prosecutors charged a Chicago nurse with allegedly distributing counterfeit Ozempic that was not manufactured by Novo Nordisk and contained no semaglutide.
In a related online weight-loss injectable case, a victim developed lesions and testing confirmed Mycobacterium abscessus contamination. DOJ described the injuries as significant and potentially life-threatening. The product in this case was not a peptide.
Reports associated with a product do not alone prove the product caused the event. They still provide an important signal—especially where mandatory reporting is limited.
FDA adverse-event reports associated with compounded semaglutide through May 31, 2026. FDA notes likely underreporting and does not claim every report proves causation.
FDA adverse-event reports associated with compounded tirzepatide through May 31, 2026, again without an automatic causal conclusion.
FDA described compounded semaglutide patients administering five to twenty times the intended dose, with some requiring medical care or hospitalization.
FDA’s July 2026 review identified reports including injection-site redness and swelling, shortness of breath prompting an emergency-room visit, and diffuse skin and gum darkening after a BPC-157/TB-500 combination. The reports cannot establish causation. FDA also cited insufficient long-term safety information and concerns about impurities, aggregation and immunogenicity.
Read FDA evaluationFDA found no human clinical exposure data or human adverse-event case reports for TB-500 in its review. FDA described theoretical immune risks that can be severe, but this is not proof that such an event has occurred in a patient using TB-500.
Read FDA evaluationFDA warning letters issued March 31, 2026 said that research disclaimers did not overcome evidence that retatrutide, tirzepatide and related products were being marketed for human use. FDA warned that injectable products can create serious and life-threatening risk when quality is not assured.
FDA’s Pharmacy Compounding Advisory Committee materials proposed not adding BPC-157, KPV, TB-500, MOTS-c, emideltide, Epitalon and Semax—free base and acetate forms—to the 503A bulk drug substances list. A proposal or advisory vote is not the same as a final FDA determination; this bulletin will track the final agency action.
Read the FDA briefing documentA qualified clinician, a valid prescription and a traceable, properly regulated pharmacy are essential parts of treatment—not optional extras.
